Osimertinib (CAS 1421373-65-0)
Alternate Names:
AZD 929; N-[2-[[2-(dimethylamino)ethyl]methylamino]-4-methoxy-5-[[4-(1-methyl-1H-indol-3-yl)-2-pyrimidinyl]amino]phenyl]-2-propenamide
CAS Number:
1421373-65-0
Molecular Weight:
499.6
Molecular Formula:
C28H33N7O2
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
QUICK LINKS
Ordering Information
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
Osimertinib (CAS 1421373-65-0) References
- Population pharmacokinetics and exposure-response of osimertinib in patients with non-small cell lung cancer. | Brown, K., et al. 2017. Br J Clin Pharmacol. 83: 1216-1226. PMID: 28009438
- Investigating Novel Resistance Mechanisms to Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib in Non-Small Cell Lung Cancer Patients. | Yang, Z., et al. 2018. Clin Cancer Res. 24: 3097-3107. PMID: 29506987
- Preclinical Comparison of the Blood-brain barrier Permeability of Osimertinib with Other EGFR TKIs. | Colclough, N., et al. 2021. Clin Cancer Res. 27: 189-201. PMID: 33028591
- Intercellular transfer of exosomal wild type EGFR triggers osimertinib resistance in non-small cell lung cancer. | Wu, S., et al. 2021. Mol Cancer. 20: 17. PMID: 33461557
- INSIGHT 2: a phase II study of tepotinib plus osimertinib in MET-amplified NSCLC and first-line osimertinib resistance. | F Smit, E., et al. 2022. Future Oncol. 18: 1039-1054. PMID: 34918545
- Osimertinib: A Review in Completely Resected, Early-Stage, EGFR Mutation-Positive NSCLC. | Frampton, JE. 2022. Target Oncol. 17: 369-376. PMID: 35713772
- Acquired Resistance to Osimertinib in EGFR-Mutated Non-Small Cell Lung Cancer: How Do We Overcome It? | Bertoli, E., et al. 2022. Int J Mol Sci. 23: PMID: 35805940
- Osimertinib for EGFR-Mutant Non-Small-Cell Lung Cancer Central Nervous System Metastases: Current Evidence and Future Perspectives on Therapeutic Strategies. | Popat, S., et al. 2023. Target Oncol. 18: 9-24. PMID: 36652172
- Anlotinib combined with osimertinib reverses acquired osimertinib resistance in NSCLC by targeting the c-MET/MYC/AXL axis. | Lei, T., et al. 2023. Pharmacol Res. 188: 106668. PMID: 36681369
- Recent Insights into Osimertinib Analogues against EGFR Positive Non-small Cell Lung Cancer. | Chhabra, J., et al. 2023. Curr Top Med Chem. 23: 2001-2026. PMID: 37272462
Inhibitor of:
3100002L24Rik, 4.1N, 9330159F19Rik, AI987662, Arxes2, BZW1, Cid, CLU1, DDR2, EB2, EFR3A, EGFLAM, EGFR, Epiregulin, EXT1, H2-22, HuR, Lefty, LNX4, Lung Carcinoma, MAGE-D4B, Mig-6, NET-4, Olfr1354, Olfr208, Olr1029, Olr1052, Olr1061, Olr1063, Olr113, Olr119, Olr1204, Olr1235, Olr1245, Olr1259, Olr129, Olr1292, Olr1350, Olr1384, Olr1398, Olr1560, Olr1564, Olr157, Olr164, Olr1642, Olr165, Olr1739, Olr223, Olr307, Olr322, Olr348, Olr357, Olr363, Olr37, Olr375, Olr484, Olr496, Olr517, Olr541, Olr559, Olr560, Olr653, Olr684, Olr726, Olr744, Olr766, Olr775, Olr785, Olr791, Olr838, Olr943, PATE-N, Per1, Rag D, Sp3, SPANX-A-E, T3JAM, TDF, TFIP11, TLCD1, TMC3, Tmem217, Top3, TREM-2c, TTYH1, UMPS, XKRY2, YPEL, and ZFY.Activator of:
ISGF-3γ p48.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Osimertinib, 5 mg | sc-507355 | 5 mg | $86.00 |